SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QuestCor QSC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: R F B, Jr. who wrote (13)12/13/1996 5:50:00 PM
From: john e vanden biesen   of 120
 
CYPROS RELEASED RESULTS OF PHASE 2 TRIALS OF CPC-111 USE IN BYPASS SURGERY(HEART) IN OCT. GOOD RESULTS
REDUCTION IN CKMB LEVELS 30% AND REDUCTION IN ICU STAY 40% ALSO LESS SUPPORT NEEDED TO INCREASE STROKE VOLUME OF HEART ALL INDICATING REAL REDUCTION IN HEART MUSCLE DAMAGE.i WOULD ALSO LIKE TO SEE RESULTS OF ANGIOPLASTY STUDIE SOON BECAUSE IF AN ARTERY COLLAPSES EMERGENCY BYPASS IS INDICATED IF CPC-111 WORKS AS INDICATED ALL ANGIO PATIENTS COULD GET A DOSE
johnv.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News